InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 192390

Tuesday, 10/14/2014 6:55:06 PM

Tuesday, October 14, 2014 6:55:06 PM

Post# of 346390
David Carbone - Peregrine Pharmaceuticals KOL

Australian Lung Cancer Conference (ALCC)
Brisbane Convention Center
Oct 16-18, 2014

7:30 - 8:30
Bristol Myers Squibb breakfast symposium


David Carbone
Friday, Oct 17, 2014
10:00 AM
Early Detection with Biomarkers


David Carbone
Saturday, Oct 18, 2014 (Sponsored by Bristol Myers Squibb)
9:15 AM
Lung Cancer: Immunotherapy Update

http://www.alcc.net.au/wp-content/uploads/2014/10/ALCC-Finalised-Program.pdf



Looks like we move Soon... prepare the rocket

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News